<DOC>
	<DOCNO>NCT00775372</DOCNO>
	<brief_summary>To compare single-dose oral bioavailability clarithromycin 250 mg/5 mL powder oral suspension Ranbaxy Laboratories Biaxin 250 mg/5 mL granules oral suspension healthy , adult , human , male subject feed condition</brief_summary>
	<brief_title>Bioequivaelnce Study Clarithromycin 250 mg/5 mL Powder Oral Suspension Under Fed Conditions</brief_title>
	<detailed_description>The study conduct open label , balance , randomise , two-treatment , four-period , two-sequence , single-dose , crossover fully replicate , bioavailability study clarithromycin formulation compare clarithromycin 250 mg/5 mL powder oral suspension Ranbaxy Laboratories BiaxinÂ® granules 250 mg/5 mL oral suspension healthy , adult , human , male subject feed condition A single oral dose clarithromycin 250 mg/5 mL administer period supervision train Medical Officer . During course study , safety parameter include vital sign , physical examination , medical history , clinical laboratory safety test ( haematology , biochemical parameter ) assess , clinical laboratory safety test ( hematology &amp; biochemical parameter ) perform end study .</detailed_description>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>Be age range 1845 year . Be neither overweight underweight his/her height per Life Insurance Corporation India height/weight chart nonmedical case . Have voluntarily give write informed consent participate study . Be normal health determine medical history physical examination subject perform within 21 day prior commencement study . History allergy clarithromycin , erythromycin related macrolides . History severe diarrhoea within 2 week precede Day 1 study . Any evidence organ dysfunction clinically significant deviation normal , physical clinical determination Presence disease marker HIV 1 2 , Hepatitis B C viruses syphilis infection . Presence value significantly different normal reference range ( define Appendix 5 ) and/or judge clinically significant haemoglobin , total white blood cell count , differential WBC count platelet count . Positive urinary screen test drug abuse ( opiates cannabinoids ) Presence value significantly different normal reference range ( define Appendix 5 ) and/or judge clinically significant serum creatinine , blood urea nitrogen , serum aspartate aminotransferase ( AST ) , serum alanine aminotransferase ( ALT ) , serum alkaline phosphatase , serum bilirubin , plasma glucose serum cholesterol . Clinically abnormal chemical microscopic examination urine define presence RBC , WBC ( &gt; 4/HPF ) , glucose ( positive ) protein ( positive ) . Clinically abnormal ECG Chest Xray . QTc interval beyond normal limit History serious gastrointestinal , hepatic , renal , cardiovascular , pulmonary , neurological haematological disease , diabetes glaucoma . History psychiatric illness may impair ability provide write informed consent . Regular smoker smoke 10 cigarette daily difficulty abstain smoke duration study period . History drug dependence excessive alcohol intake habitual basis 2 unit alcoholic beverage per day ( 1 unit equivalent half pint beer 1 glass wine 1 measure spirit ) difficulty abstain duration study period . Use enzyme modifying drug within 30 day prior Day 1 study . Participation clinical trial within 12 week precede Day 1 study . A haemoglobin concentration le 7 % low limit reference range e.g . 13 gm % reference range 1418 gm screening .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Bioequivalence study clarithromycin 250mg/5mL powdder</keyword>
</DOC>